Sodium polystyrene sulfonate
Kayexalate (sodium polystyrene sulfonate) is a small molecule pharmaceutical. Sodium polystyrene sulfonate was first approved as Kayexalate on 1982-01-01. It is used to treat hyperkalemia in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sodium polystyrene sulfonate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KAYEXALATE | Concordia Laboratories | N-011287 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| sodium polystyrene sulfonate | ANDA | 2023-04-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyperkalemia | HP_0002153 | D006947 | E87.5 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dental pulp necrosis | D003790 | K04.1 | 3 | — | — | 1 | — | 4 | |
| Sepsis | D018805 | A41.9 | — | — | 1 | 1 | 2 | 4 | |
| Gram-negative bacterial infections | D016905 | — | — | 1 | 1 | — | 2 | ||
| Periapical abscess | D010482 | EFO_1001202 | — | — | — | 1 | — | 1 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | — | 1 |
| Conjunctivitis | D003231 | H10 | — | — | — | 1 | — | 1 | |
| Cross infection | D003428 | — | — | — | 1 | — | 1 | ||
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | 1 | — | 1 |
| Actinic keratosis | D055623 | L57.0 | — | — | — | 1 | — | 1 | |
| Septic shock | D012772 | A48.3 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 2 | 1 | — | 1 | 3 |
| Critical illness | D016638 | — | — | 1 | — | 1 | 2 | ||
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | 1 | 2 | |
| Burns | D002056 | T30.0 | — | 1 | 1 | — | 1 | 2 | |
| Healthcare-associated pneumonia | D000077299 | — | 1 | 1 | — | — | 1 | ||
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 1 | 1 | — | — | 1 |
| Bacterial conjunctivitis | D003234 | EFO_1000829 | H10.0 | — | — | 1 | — | — | 1 |
| Wounds and injuries | D014947 | T14.8 | — | — | 1 | — | — | 1 | |
| Eczema | D004485 | HP_0000964 | L30.9 | — | — | 1 | — | — | 1 |
| Edema | D004487 | R60.9 | — | 1 | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | — | — | 1 | 2 |
| Leber congenital amaurosis | D057130 | Orphanet_65 | H35.5 | 1 | 1 | — | — | — | 1 |
| Hematopoietic stem cell transplantation | D018380 | — | 1 | — | — | — | 1 | ||
| Acute disease | D000208 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Corneal diseases | D003316 | H18.9 | — | — | — | — | 1 | 1 | |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 1 | 1 |
| Respiratory tract infections | D012141 | J06.9 | — | — | — | — | 1 | 1 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
| Gestational diabetes | D016640 | HP_0009800 | O24.4 | — | — | — | — | 1 | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 1 | 1 |
| Herpes simplex | D006561 | B00 | — | — | — | — | 1 | 1 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Infectious skin diseases | D012874 | — | — | — | — | 1 | 1 | ||
| Pituitary neoplasms | D010911 | — | — | — | — | 1 | 1 |
Show 15 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SODIUM POLYSTYRENE SULFONATE |
| INN | — |
| Description | Polystyrene sulfonates are a group of medications used to treat high blood potassium. Effects generally take hours to days. They are also used to remove potassium, calcium, and sodium from solutions in technical applications.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 123333-94-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201484 |
| ChEBI ID | — |
| PubChem CID | 75905 |
| DrugBank | DB01344 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,879 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,330 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more